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CTX-M-14-type extended-spectrum -lactamase was first detected in Salmonella enterica serovar London
strains which were isolated from three hospitalized pediatric patients with gastroenteritis. The isolates
had pulsed-field gel electrophoresis patterns identical to those of the previously isolated antimicrobial-
susceptible strains from community-acquired gastroenteritis, suggesting the susceptible clone acquired
the resistance.
Nontyphoidal salmonella (NTS) is one of the most impor-
tant enteric pathogens even in developed countries, and it may
also cause bloodstream and other extraintestinal infections for
which antimicrobial therapy is required. Salmonella spp. are
usually susceptible to many antimicrobial agents, but a recent
increase of resistance has become a concern (18). Salmonella
enterica serovar London is not a common serovar; the infection
was rarely reported, but an epidemic occurred in Hungary in
1980 (9). Only 4 of 1,306 (0.3%) Salmonella isolates were of
this serovar in 1998 in Korea (7). However, the number in-
creased to 74 in the period from 2000 to 2001 (8), indicating a
wide dissemination. In 2000, an infant formula-associated com-
munity-acquired gastroenteritis outbreak affecting 31 infants
was caused by Salmonella serovar London (16), and even a rare
endophthalmitis infection in a previously healthy 3-month-old
infant was similarly caused (20). There were no reports of
outbreaks of Salmonella serovar London infection in 2002 or
2003, but the National Institute of Health, Korea, reported
that 23 of 632 (3.6%) Salmonella isolates were of this serovar
in 2003 (http://dis.cdc.go.kr/cdmr/eng_cdmr.asp).
A small outbreak of gastroenteritis occurred, affecting three
hospitalized pediatric patients during an 11-day period in June
2004. Serogroup E Salmonella strains with cefotaxime resis-
tance were isolated from watery stool specimens, and this
prompted us to determine a possible relationship between
these strains and the recently reported Salmonella serovar
London strains (8, 16) and to determine the mechanism of
-lactam resistance.
The serovar of the isolates was determined at the Na-
tional Institute of Health, Korea. Antimicrobial susceptibil-
ity was tested by the disk diffusion method (14), and extend-
ed-spectrum -lactamase (ESBL) was screened by the
double-disk synergy test with amoxicillin-clavulanic acid ver-
sus cefotaxime and ceftazidime disks with distances of 15
mm from edge to edge. Etest strips and Etest ESBL strips
(AB BIODISK, Solna, Sweden) were used to determine
MICs of cefotaxime and ceftazidime and to confirm ESBL
production, respectively. Isoelectric points (pIs) of the
-lactamases were determined as described previously (11).
The blaTEM and blaSHV alleles were detected by PCR as
described previously (2, 10). The primers shown in Table 1
were used to detect or sequence the blaCTX-M gene with the
following conditions: 30 cycles of 94°C for 30 s, 54°C for 30 s,
and 72°C for 45 s. Proteus mirabilis strain YMC 03/01/U226,
which harbors the blaCTX-M-14 gene, was used as a positive
control. The sequencing was performed as reported previ-
ously (11). Resistance transfer was tested by both broth- and
plate-mating methods using an azide-resistant recipient,
Escherichia coli strain J53. Pulsed-field gel electrophoresis
(PFGE) of XbaI-restricted genomic DNA was performed
according to the manufacturer’s instructions (Bio-Rad, Her-
cules, Calif.), and the patterns were visually compared with
those of recently reported Salmonella serovar London
strains (8, 16).
The three patients developed diarrhea 4, 17, and 22 days
after hospitalization, respectively (Table 2). All three Salmo-
nella isolates from the patients were identified as Salmonella
serovar London. However, contrary to the previously reported
strains (8), the isolates were resistant to ampicillin, cefotaxime,
aminoglycosides, and trimethoprim-sulfamethoxazole. ESBL
production was suspected by the double-disk synergy test, and
the MICs by Etest, i.e., 256 g/ml for cefotaxime, 0.25 g/ml
for cefotaxime-clavulanic acid, 3 to 6 g/ml for ceftazidime,
and 0.38 g/ml for ceftazidime-clavulanic acid, suggested the
enzyme being of the CTX-M type. All three isolates had -
* Corresponding author. Mailing address: Department of Labora-
tory Medicine, Yonsei University College of Medicine, 134 Shinchon-
dong, Seodaemun-ku, Seoul 120-752, Korea. Phone: 82-2-361-5866.
Fax: 82-2-313-0908. E-mail: leekcp@yumc.yonsei.ac.kr.
3519
lactamase bands of pIs 5.4 and8.0. The blaTEM and blaCTX-M
alleles, but not the blaSHV allele, were detected by PCR, and
the sequences were identical to those of blaTEM-1 and
blaCTX-M-14.
A majority of the ESBL-producing Salmonella isolates have
been Salmonella enterica serovar Typhimurium (4) and Salmo-
nella enterica serovar Enteritidis (17). Nosocomial infections
caused by ESBL-producing NTS are not often reported (4). In
Korea, a few isolates of TEM-52-type ESBL-producing NTS
were reported, but they were not Salmonella serovar London
(10).
Among the six groups of CTX-M enzymes (1), the CTX-
M-1, -2, and -9 groups have been reported in serovars Typhi-
murium, Virchow, Enteritidis, Kentucky, Infantis, and
Oranienburg (1, 3, 5, 12, 19). However, to the best of our
knowledge this is the first report of a CTX-M-14 enzyme-
producing Salmonella serovar London, which suggests a grad-
ual spread of this resistance to various serovars of Salmonella.
ESBL genes have the potential to spread to other organisms
because they reside on plasmids or in class 1 integrons (1, 3).
Repeated attempts failed to transfer the cefotaxime resistance
by conjugation, as was reported with other CTX-M-type
ESBL-producing isolates (4).
The PFGE patterns of XbaI-digested genomic DNA of all
three blaCTX-M-14-positive isolates in this study were identical,
suggesting an outbreak by a single clone (Fig. 1). We could not
determine the origin of the outbreak. The pattern was also
identical to that from community-acquired pediatric patients
(8, 16), suggesting an identical clone had been spreading.
However, it is interesting that our isolates were multidrug
resistant, while the other strains reported were susceptible
to multiple antimicrobial agents, including ampicillin. Acqui-
sition of blaTEM-52 by NTS during hospitalization was docu-
mented in a previous study (9). The Salmonella serovar Lon-
don strains in this study also probably acquired the blaCTX-M
gene from other gram-negative bacilli. CTX-M-14 enzyme-
producing Klebsiella pneumoniae and E. coli isolates were de-
tected from blood at the same hospital (15).
Antimicrobial treatment for NTS gastroenteritis is gener-
ally not required, but treatment with ceftriaxone or tri-
methoprim-sulfamethoxazole is recommended if a patient is
under six months or over 50 years of age or has underlying
diseases (6). Two of our patients did not receive antimicro-
bial therapy for the gastroenteritis until the persistence of
the organisms for 9 and 24 days was known, which provided
ample opportunity to disperse the strains. Fluoroquinolone
is not a recommended drug for pediatric patients, but a
short treatment with oral ciprofloxacin is considered safe
and allows a rapid recovery (13). The isolates were suscep-
tible to nalidixic acid, and ciprofloxacin therapy eliminated
the Salmonella from two patients. The one remaining pa-
tient received cefazolin for the treatment of other condi-
tions but did not receive any antimicrobial agent to treat
gastroenteritis because she was discharged before the Sal-
monella isolation report was available.
In conclusion, the CTX-M-14-type extended-spectrum
-lactamase was first detected in Salmonella serovar London
strains which were isolated from three hospitalized pediatric
patients with gastroenteritis. The isolates had PFGE pat-
terns identical to those of the previously isolated antimicro-
bial-susceptible strains from community-acquired gastro-
enteritis, suggesting the susceptible clone acquired the
resistance.
TABLE 1. Primers used to detect and sequence CTX-M-type ESBL genes
PCR
target Utility Primer Nucleotide sequence (5 to 3)
Position of
primer
Expected
size (bp)
GenBank
accession
no.
Source or
reference
CTX-M Detection CTX-Uni-F CVA TGT GCA GYA CCA GTA A 209–227 585 AJ416341 A. Bauernfeinda
CTX-Uni-R ARG TSA CCA GAA YMA GCG G 775–793
CTX-M-1 Detection CTX-M-1 Gr-F TCA ATG GGA CGA TGT CAC TG 350–366 500 X92506 This study
group CTX-M-1 Gr-R CGC CGA CGC TAA TAC ATC G 831–849
CTX-M-2 Detection CTX-M-2 Gr-F AAA GTG ACG GCG TTT GCT C 448–466 360 X92507 This study
group CTX-M-2 Gr-R CGG TTG GGT AAA GTA GGT CAC 787–807
CTX-M-8 Detection CTX-M-8 Gr-F AGA CGC TTC GCA ATC TGA C 572–590 236 AF189721 This study
group CTX-M-8 Gr-R TGG CTG GGT GAA GTA AGT G 789–807
CTX-M-9 Detection CTX-M-9 Gr-F GAT GAA CGC TTT CCA ATG T 196–214 463 AJ416345 This study
group CTX-M-9 Gr-R CGG TCG TAT TGC CTT TGA G 640–658
CTX-M-14 Sequencing CTX-M-14-F1 GAG TGT TGC TCT GTG GAT AAC 227 to 207 1,347 AF252622 11
CTX-M-14-R2 GGC AAG GTC AGA ATA GCG CTG 224–244
CTX 14S-F AAA AAT GAT TGA AAG GTG GTT GT 162 to 131 This study
CTX 14S-R TTA CAG CCC TTC GGC GAT GA 857–876
CTX 14S-Seq-F TGG CTC AAA GGC AAT ACG A 637–655
a Personal communication.
TABLE 2. Clinical features of the gastroenteritis patients infected with ESBL-producing Salmonella serovar London isolates
Case no. Age/sex Underlying disease Department Admissiondate
Date of Salmonella
culture/persistence Treatment/outcome
1 18 mo/male Acute lymphocytic leukemia Hematooncology 1 June 2004 18 June 2004/9 days Ciprofloxacin/cured
2 4 yr/male Ganglioneuroblastoma Hematooncology 6 June 2004 28 June 2004/24 days Ciprofloxacin/cured
3 3 mo/female Meningocele Neurosurgery 19 June 2004 23 June 2004/unknown Cefazolin/unknown
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FIG. 1. Comparison of PFGE patterns of XbaI-digested genomic
DNA of Salmonella serovar London isolates. (A) Two antimicrobial-
susceptible strains isolated from infants (8). (B) Three CTX-M-14-
producing strains in this study. The patterns are apparently identical,
although the PFGE conditions were different: an initial 2.2 s and a final
63.8 s for 16 h (for panel A) and an initial 0.5 s and a final 60 s for 20 h
(for panel B).
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